Introduction
antibodies (MAbs). By definition, MAbs are a class of highly specific Abs produced by the clones of a single hybrid cell formed in the laboratory by the fusion of B-lymphocytes with a tumor cell.
MAbs are also known as 'magic bullet'.
[1] The idea of 'magic bullet' was first proposed by Paul Ehrlich who at the beginning of the 20 th century figured 'if a compound could be made to selectively target a disease causing organism, then a toxin for that organism could be delivered along with the agent of selectivity'. The market for therapeutic MAbs is a most potential sector within the pharmaceutical industry. These antibodies are forecast to drive the market towards the $30 billion mark by the year 2011 due to a high level of innovation. Several MAbs are set to be launched in the next 5 years. Experimental cancer studies have used various substances attached to MAbs such as radioactive material, drugs, immune system to take an 'active' role in fighting the cancer.
The development of the immortal hybridoma requires the use of animals. No method of generating a hybridoma that avoids the use of animals has been found. Recent in vitro techniques allow the intracellular production of antigen-binding antibody fragments, but such techniques are still experimental and have an uncertain yield, efficacy and antibody function. [3] There are two methods for growing these cells: injecting them into the peritoneal cavity of a mouse or using in vitro cellculture techniques.
[4]
Production of MAbs
The process of producing MAbs was invented by Kohler and Milstein in 1975 .
[5] They shared the Nobel Prize in Physiology/Medicine in 1984 for the discovery of MAb. The key idea was to use a line of myeloma cells that had lost the ability to secrete antibodies. They came up with a technique to fuse these cells with healthy antibody producing B cells. This fusion resulted in a clone of cells that retained the myeloma cell lines and ability to live indefinitely in tissue culture. The procedure yielded a cell line capable of producing one type of antibody protein for a long period. The fused cell was called a hybridoma and produced large quantities of MAbs.
Production in animals [ Figure 1 ] When injected into a mouse, the hybridoma cells multiply and produce fluid (ascites) in its abdomen. This fluid contains a high concentration of antibody. The mouse ascites method is inexpensive and easy to use. However, if too much fluid accumulates or if the hybridoma is an aggressive cancer, the a hollow fiber or a membrane, with a low-molecular-weight cutoff (10,000-30,000 kD), called semipermeable-membrane based system permits cells to grow at high densities in culture. The objective of this system is to isolate the cells and MAbs produced in a small chamber separated by a barrier from a larger compartment that contains the culture media. Culture can be supplemented with numerous factors that help optimize growth of the hybridoma. These methods produce MAbs in concentrations often as high as those found in ascitic fluid and are free of mouse ascitic fluid contaminants. These methods reduce the use of animals and are the methods of choice for large-scale production by the pharmaceutical mouse will likely experience pain or distress. If a procedure industry because of the ease of culture. [7, 8] produces pain or distress in animals, regulations call for a Although in vitro techniques can be used for more than search for alternatives. The mouse ascites method usually 90% of MAb production, it must be recognized that there are produces very high MAbs concentration that often does not situations in which in vitro methods will be ineffective, as some require further concentration procedures that can denature hybridomas do not grow well in culture or are lost in culture. antibody and decrease effectiveness. It avoids the effects of Because hybridoma characteristics vary and MAb production contaminants as in in vitro batch-culture fluid method and no needs are diverse, in vitro techniques are not suitable in all expert guidance is required to teach the method. However, it situations. These techniques might impede research, involves the continued use of mice requiring daily observation especially if large numbers of MAbs are to be screened for and the MAbs produced contains various mouse proteins and efficacy or specificity in the treatment of diseases. In vitro other contaminants that might require purification.
[6]
methods generally require the use of fetal calf serum, which limits some antibody uses and which is a concern from the Production in cell-culture animal-welfare perspective. The loss of proper glycosylation One alternative is to grow hybridoma cells in a tissue of the antibody (in contrast with in vivo production) might culture medium, but this technique requires some expertise, make the antibody product unsuitable for in vivo experiments special media and can be expensive and time-consuming. There because of increased immunogenicity, reduced binding has been considerable research on in vitro methods for growing affinity, changes in biologic functions or accelerated clearance hybridomas and these newer methods are less expensive, in vivo. MAbs produced by membrane-based in vitro methods faster, and produce antibodies in higher concentration than are contaminated with dead hybridoma cells and their has been the case in the past. Following are the in vitro products, thus require early and expensive purification. In production methods that are available.
vitro culture methods are generally more expensive than the Batch tissue-culture methods. The simplest approach for ascites method for small or medium-scale production of producing MAb in vitro is to grow the hybridoma cultures in MAbs. batches and purify the MAbs from the culture medium. Fetal bovine serum is used in most tissue culture media. The MAb Evolution of MAbs concentration achieved is low (around a few micrograms per
The significance of MAbs lies in their specificity and milliliter) and some MAbs are denatured during concentration immortality. Whereas hybridoma development of murine or purification process.
MAbs was the requisite for the development of MAbs as drugs, Semipermeable-membrane-based system. A barrier, either the inherent immunogenicity of rodent sequences in humans has presented obstacles to the clinical application of MAbs. Sensitization to MAb therapeutics poses significant risk to animals the patient and may blunt the efficacy of these therapies. The advent of chimeric antibodies lessened but did not eliminate the rodent content of MAbs. Thus, immunogenicity remained a concern. Further, elimination of rodent sequences enabled the production of humanized MAbs. This was followed by current technology using phage display and finally, transgenic mice technology, which allows for the generation of fully human therapeutic MAbs. The reduced immunogenicity of this new generation of MAbs is expected to enhance efficacy, safety, and ease of use. [9] The MAbs are also classified into generations as per their evolution and immunogenicity as follows: 1. First generation MAbs. Majority of the earlier MAbs available were murine, rabbit, or rat proteins purified following immunization of the animal with an antigen preparation. These were labeled as first generation antibodies. Patient often generated Abs to these foreign antigens. These host antibodies are referred to as human antimouse antibody (HAMA) or human anti-rat antibodies or human anti-rabbit antibodies (HARA). The host antibody blocked the effectiveness of therapy by prematurely clearing the treatment antibodies and limiting possibilities for future immunotherapy. [10] HAMA or HARA responses could be associated with immune-complex related adverse events, such as serum sickness or anaphylaxis. In addition, these first generation MAbs are not able to genomes are then converted into plasmids that can subsequently produce specific Fabs in bacteria. [9] (b) Transgenic mice. Transgenic technology has been exploited to make a transgenic mice that have human Ab gene loci inserted into their bodies (using embryo stem cell method) and their own genes for making antibodies 'knocked out'. Therefore, mouse can be immunized with the desired antigen and produces human Abs. [9] (c) Phage display. This is another technique for making human MAbs. It is used when MAbs do not directly recruit human effector functions such as antibodyrecognize antigen or when antigen is undetectable dependent cellular cytotoxicity (ADCC) and complementnormally and expressed only in disease. Phage dependent cytotoxicity (CDC), which cause destruction display libraries are available. [9] of a malignant cell. Plant genetic engineering has also led to the production of Second generation MAbs. To overcome the obstacles of plant-derived MAbs (MAbs P ), which provides a safe and first generation antibodies, Winter et al. pioneered the economically feasible alternative to the current methods of techniques to humanize MAbs, by removing the reactions antibody production in animal systems. Transgenic plants have that many earlier MAbs caused in some patients. [11] proven to be an efficient production system for the expression Nowadays, DNA technology or genetic engineering is used of functional therapeutic proteins. and herpes simplex virus in animals. Till date, no study has e.g., infliximab, rituximab, abciximab. [12, 13] reported the use of systemic administration of MAb P to provide Humanized Abs. Human antibody containing the immunoprotection. [14, 15] complementarity-determining region from a nonLarge scale production of MAbs human source. The Ab combines only the amino acids responsible for making the Ag binding site (the The development of a commercial monoclonal antibody hypervariable region) of a mouse Ab with the rest of production process involves much more than just scaling-up human Ab molecule thus replacing its own the laboratory process and making it cost-effective. It involves hypervariable regions, e.g., daclizumab, herceptin, establishing the hybridoma cell bank with cells that are free of vitaxin. [12, 13] adventitious agents such as viruses and mycoplasma, that have (iii) Primatized Abs. It is a composite of primate variable stability in continuous culture for antibody-production rate regions and human constant regions. [12, 13] and cell viability and that do not have unusual or expensive (iv) Genetically engineered Abs. Fab portion from rodent media requirements. The style and mode of operation of the 2.
have MAbs. [12, 13] bioreactor used to produce the antibody must be explored. The antibody-based product must be processed to high levels of purity and specific contaminants such as DNA and endotoxin must be reduced to extremely low levels. Appropriate labeling or drug conjugation methods must also be developed. The product must be formulated, so that it has performance characteristics that are stable over a reasonable period of time.
Adequate test procedures must be developed to assure product purity, activity, stability, and safety on a lot-to-lot-basis.
Compliance with drug regulations, guidelines, and procedures must be guaranteed. In the coming decade, it is likely that the two arms of biotechnology, hybridoma technology and recombinant DNA technology, will be used together to generate unique protein molecules.
[16]
Nomenclature
The United States adopted name (USAN) Council has 
Kaur et al.: Monoclonal antibodies
outlined specific guidelines for the nomenclature of MAbs. [17] These guidelines provide a foundation of knowledge about a specific MAb just by looking at the generic name.
• All MAbs end in the suffix -mab. It is used to identify a class of medicines.
• The infix preceding -mab denotes the source of the product. e.g., u = human i = primate o = mouse e = hamster a = rat xi = chimera zu = humanized • The infix preceeding the source of the Ab refers to It delivers the toxic substance to where it is needed most, minimizing damage to normal cell. The mechanism by which MAbs achieve therapeutic effect e.g., vi(r) -viral ci(r) -cardiovascular is not very clear. Potential mechanisms include: [19] ba ( 2. Cytotoxicity to the cell expressing target AG by ADCC or When combining a target or disease infix stem with the source CDC. stem for chimeric or humanized MAb the last consonant of 3. Inhibition of growth factors: Epidermal growth factor this target syllable is often dropped to make the name more receptor (EGFR) is a cell surface receptor involved in pronounceable (e.g., -tum-changed to -tu-).
regulation of cell proliferation and survival. Also new Target source MAb stem vessels grow to feed the cancer cells through this factor. e.g., ci(r) -xi -mab Abciximab Theses factors can be inhibited to arrest growth of cancer tu(m) -zu -mab Trastuzumab cells e.g., cetuximab act as EGFR inhibitor.
• The starting prefix is a distinct syllable carrying no special Pharmacokinetics meaning and unique for each drug. If the product is MAbs are used by intravascular route and remain essentially radiolabeled or conjugated to another chemical such as a intravascular. Intravenous injection may not always be toxin, a separate word is used to identify the conjugate.
appropriate for long-term treatment for a variety of reasons.
Types of MAbs that are used in treatment
Hour-long infusions require a hospital environment and are often associated with mild to very severe side effects. [19] Continuous and sustained delivery of antibodies can lead to These are those without any drug or radioactive material induction of neutralizing anti-idiotypic immune responses, attached to them. They attach themselves to specific Ag on which sometimes develop when massive doses of purified cells, e.g. cancer cells. They mark the cancer cells for the immunoglobulins are repeatedly injected into patients. immune system to destroy it. Others attach to certain Ag Additionally, the bioavailability of therapeutic antibodies is often sites called receptors where other molecules that stimulate detrimental to the treatment efficacy. They have small volume the cancer cell growth might otherwise attach. By blocking of distribution and limited tissue penetration. They remain in other molecules from attaching there, MAbs prevent cancer circulation for 2 days to 2 weeks. Another limitation is the high cells from growing rapidly. Some examples of naked MAbs cost of recombinant proteins certified for human use. [19] available for use are: Antibodies can have exquisite specificity of target
Naked MAbs
1. Trastuzumab -For advanced breast cancer 2. Rituximab -For B cell non-Hodgkin's lymphoma 3. Cetuximab -For advanced colorectal cancer 4. Bevacizumab -For metastatic colorectal cancer 5. Alemtuzumab -For B cell chronic lymphocytic leukemia
Conjugated MAbs
MAbs, because of their inherent specificity, are ideal targeting agents. They can be used to deliver radionuclides, toxins, or cytotoxic drugs to a specific tissue or malignant cell population. These are attached to drugs toxins or radioactive atoms. [18] They are also referred to 'tagged' 'labeled' or 'loaded' antibodies. MAbs with radioactive particles attached are referred to as radiolabeled and this type of therapy is known as radioimmunotherapy. MAbs attached to toxins are known as immunotoxins. The MAb acts as a homing device, circulating in the body until it finds a cancer cell with a matching antigen.
recognition and thus generate highly selective outcomes following their systemic administration. While antibodies can have high specificity, the doses required to treat patients, particularly for a chronic condition, are typically large. Fortunately, advances in production and purification capacities have allowed for the exceptionally large amounts of highly purified MAbs to be produced. Additionally, genetic engineering of antibodies has provided a stable of antibodylike proteins that can be easier to prepare.
Genetic manipulations of the immunoglobulin molecules are effective means of altering stability, functional affinity, pharmacokinetics, and biodistribution of the antibodies required for the generation of the 'magic bullet. ' 
Adverse effects
Adverse effects with MAbs are related to one of three mechanisms: [20] ) .
1. Xenogenetic nature of MAb used 2. Suppression of physiological function 3. Activation of inflammatory cells or mediators after binding of MAb to its target Adverse effects with naked MAbs are usually mild and often related to an 'allergic' reaction and occur while the drug is being first infused. This reaction is attributed to massive cytokine release resulting from transient activation of T lymphocytes. [19] Reactions may include fever, chills, weakness, headache, nausea, vomiting, diarrhea, low blood pressure, and rashes. Some MAbs cause leucopenia, thrombocytopenia, and anemia. Conjugated MAbs cause more side effects and the Although T cells reappear in the circulation during the course of treatment, these cells are CD3-negative and are not capable of T-cell activation. However, the use of OKT-3 was hampered due to production of Ags and rapid clearance from circulation. This led to development of humanized OKT-3 which is under investigation.
[27]
Acute graft rejection is a T-cell mediated immune response and depends on presence of IL-2. IL-2 binds to IL-2 receptor. In the search for more specific immunosupression with MAb L-2 Receptor (IL-2R), that is expressed on T-cells, which were chosen as target. Chimeric and humanized MAbs, basiliximab, and daclizumab were developed to bind to ILactual effects depend to which substance it is attached. 2R. They competitively antagonized IL-2 or caused Sometimes it also causes suppression of physiological function elimination of activated T-cells. They have been efficacious in depending on specificity of tissue targets. Thus antipreventing acute rejection episode after renal transplant. [28- lymphocytes MAb cause immunosupression. There is also an 30] Table 1 lists the MAbs used in immunosupression. increased risk of infection and cancer development. AntiTNFAutoimmune diseases -inhibition of autoimmune reactivity α MAb treatment has been reported to increase the reactivation For the treatment of autoimmune disease, MAbs need to of tuberculosis because it interferes with the cellular response target immune response cells, i.e., B or T-cells. MAb may against mycobacteria and this adverse effect is more in areas function as an immunosuppressant by removing activated with high incidence of tuberculosis.
[21] AntiTNF-α MAb cells, blocking their function or normalizing elevated levels of treatment also leads to development of lymphomas. [22] proinflammatory cytokine. Therapeutic targets in this Rituximab may lead to depletion of plasma cells and cause condition include T-cell surface Ags, T-cells activation Ags, hypogammaglobulinemia due to its action on B-cells. [23] molecules involved in T/B cell interaction, adhesion
Therapeutic Potentials of MAbs
molecules, and cytokines. The most promising result emerged from TNF MAbs were being used in laboratory research and in medical therapy in rheumatoid arthritis (RA) and Crohn's disease. tests since the mid 1970s, but their effectiveness in disease TNF is a cytokine produced by activated monocytes and treatment was limited. MAbs created much excitement in the macrophages. The cytokine is actively produced at the medical world and in the financial world in 1980s especially as synovial and mucosal sites of inflammation in RA and Crohn's a potential cure for cancer. Although this resulted in great disease. It is involved in vasodilation, increased vascular optimism that a therapeutic 'magic bullet' could be engineered, permeability, and activation of platelets and regulation of success with MAbs was many years away. By early 21 st century, production of acute phase proteins involved in inflammation. several drugs based on MAbs were introduced for a wide variety TNF is also actively produced in various infectious diseases of therapeutic uses. Herceptin, a humanized MAb for breast such as sepsis, malaria, adult respiratory disease syndrome, cancer treatment, became the first drug designed by and AIDS. biomolecular engineering approach to be approved by the TNF is considered to have an important role in FDA.
[24] A recent survey suggested that ¼ of all biotech drugs autoimmune inflammatory disease. [31, 32] in development are MAb based. [19] At least an additional discovery of infliximab which is a chimeric MAb and found to 400 MAbs are under clinical trials to treat cancer, transplant be effective in various animal models and clinical trail for RA rejection or to combat autoimmune or infectious diseases. [25] and Crohn's disease. It is clinically beneficial in Crohn's It is now possible to obtain engineered antibodies, chimeric, disease, reduces the response duration and also reduces -α blocking This led to the or humanized or fully human MAbs via the use of phage display technology or of transgenic mice. Important therapeutic implications of MAbs are given in the preceding chapter.
Immunosupression -inhibition of alloimmune reactivity
In 1985, Muromonab CD-3 (OKT3) a murine MAb, was the first to be approved by the US FDA for clinical use in humans, for prevention of graft rejection in renal transplant patient.
[26] As first line or in steroid resistance rejection therapy, OTK3 has proved efficacious and improved graft survival. It specifically reacts with the T-cell receptor-CD3 complex on the surface of circulating human T cells.
[27] OKT3 binds to a glycoprotein (the 20-kd epsilon chain) on the CD3 complex to activate circulating T cells, resulting in transient activation of T cells, release of cytokines and blocking of Tcell proliferation and differentiation. Nearly all functional T cells are transiently eliminated from the peripheral circulation. fistula formation. [33, 34] The first trail of usefulness of infliximab [ Table 1 ] in RA was shown in 1994. [35] Infliximab halts radiographic progression of RA and also clinically cures the disease.
[36,37] Adalimumab, a humanized IgG1 MAb is also approved for the treatment of RA. It binds to soluble and cell membrane-bound TNF-α. It is proved to be efficacious and halts radiological progression of the disease.
[38,39] Anti TNF-α MAb treatment has shown promise in patients with seronegative spondyloarthropathies and psoriatic arthritis. [40] [41] [42] Anti-IL-6 and anti-IL-6 receptor MAbs have also been found to be useful in RA as IL-6 is elevated in patients with RA and levels of RA correlates with disease activity and extent of joint erosion. [43, 44] 
Cancer
Classical therapeutic modalities such as surgery, radiation, and chemotherapy not only fail to cure the great majority of malignant tumors, but also their employment often leads to severe and debilitating side effects. Immunotherapy as a fourth modality of cancer therapy has already been developed and proven to be quite effective. Strategies for the employment of antibodies for anti-cancer immunotherapy include: (1) Immune reaction directed destruction of cancer cell, (2) interference with the growth and differentiation of malignant cells, (3) antigen epitope directed transport of anti cancer agents to malignant cells, (4) anti-idiotype vaccines, and (5) development of engineered (humanized) mouse monoclonals for anti-cancer therapy. In addition, a variety of different agents (e.g., toxins, radionuclides, chemotherapeutic drugs, etc.) have been conjugated to mouse and human MAbs for selective delivery to cancer cells. [45] Unconjugated antibodies show significant efficacy in the treatment of breast cancer, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. Promising new targets for unconjugated antibody therapy include cellular growth factor receptors, receptors, or mediators of tumor-driven angiogenesis and B cell surface antigens other than CD20. One immunoconjugate containing an antibody and a chemotherapy agent exhibits clinically meaningful anti-tumor activity in acute myeloid leukemia.
[46] Clinical trials of MAb therapy are in progress for almost every type of cancer. Rituximab was the first MAb used for treatment of cancer [ Table 2 ]. It is chimeric IgG-1 MAb directed against CD20, which is a transmembrane protein on mature B-lymphocytes. Its efficacy has been demonstrated against low grade and follicular non-Hodgkin's lymphoma relapse.
[47] Rituximab has also been useful in Waldenstrom's macroglobulinemia, posttransplantation lymphoma, and multiple myeloma. [48] [49] CD52 MAb (Campath 1H) has also been studied to lyse malignant hemopoetic cells. [50] CD52 MAb provides an effective therapy for chronic leukemia of T-cell or B-cell origin that is resistant to conventional chemotherapy. Anti-tumor therapy with MAbs targets growth factor receptor too.
Angiogenesis also plays a central role in the growth and metastasis of cancers. Antibodies directed against EGFR directly inhibit the growth of tumors bearing such receptors. Trastuzumab, a humanized Ab targets HER2 receptor found in breast cancer. It is the first MAb approved by US FDA for generated endothelial cells.
[52] In Phase II clinical trial it has shown promise in shrinking solid tumors. Bevacizumab which blocks the vascular endothelial growth factor (VEGF) receptor has been approved by US FDA for the treatment of colorectal cancer. [53] Bevacizumab has shown promising results in clearcell renal cancer in various clinical trials. [54] The promising result of naked and conjugated type MAb in cancer may make MAb therapy significant in the management of these patients. It is expected that MAb-based immunotherapy may be accepted as a conventional form of therapy and employed not only in terminal cancer patients but also, in other instances like, during and following surgical resection.
Generic name
Trade the treatment of solid tumors.
[51] Trastuzumab blocks HER2 Antiplatelet therapy receptor action and this receptor is expressed on the surface Table 2 shows various MAbs used in therapeutics. Acute membrane of tumor cells in 30% patients with breast cancer coronary syndromes and percutneous coronary intervention and signifies poor prognosis. Strategies aimed at interfering share a common physiological mechanism of intimal with tumor blood supply offer promise for new cancer disruption and platelet aggregation. Glycoprotein IIb/IIIa therapies. Vitaxin (an anti-alpha-v/beta-3 antibody) interferes receptor antagonist which interrupt the final common with blood vessel formation by inducing apoptosis in newly pathway of platelet activation and aggregation are used for
Monoclonal antibodies approved for use in malignancy Table 2 MAb acute therapy. Abciximab was the first antagonist to be evaluated [ Table 1 ]. It inhibits the clumping of platelets by binding to surface receptors that normally are linked by fibrinogen. It is helpful in preventing the reclogging of the coronary arteries.
[ [55] [56] [57] Infectious disease Palivizumab, a humanized MAb directed against Respiratory Syncytial virus is used for the treatment of premature infants and infants with bronchopulmonary dysplasia [ Table 1] . [58] A MAb was also found to be useful to cure West Nile fever in mice. [59] Opthalmological disorders and thus could slow the disease progression. [67] Refractory Wegener's granulomatosis Humanized antilymphocyte MAbs may provide an effective treatment in patients with systemic vasculitis which is refractory or intolerant to steroids or cytotoxic agents.
[68]
Systemic lupus erythematosus (SLE)
IL-6 levels are elevated in human and murine SLE. Blocking the action of IL-6 ameliorates disease activity in murine model of SLE. A humanized MAb is in Phase I of clinical trial. T cells, B cells and monocytes from patients with SLE expressess CD40 L on their surface which have been found to produce autoantibodies in vitro.
[69] Therefore, humanized anti-CD40L Daclizumab has shown to be efficacious for noninfectious IDEC-131 was tried for SLE but not found to be successful. [70] uveitis. [60] Ranibizumab (Lucentis) is a recombinant humanized Another humanized anti-CD40L Mab, ruplizumab was effective IgG1 kappa isotype monoclonal antibody fragment designed in SLE, but increased the incidence of myocardial infarction. for intraocular use, which competitively binds and inhibits Therefore the trials were discontinued.
[71]
VEGF. Therefore, indicated for the treatment of neovascular Rituximab has also been shown to be effective in patients (wet) age related macular degeneration. [61] of SLE with glomerulonephritis, [72] by causing B-cell depletion. B-cells in SLE display abnormal signaling, express aberrant Multiple sclerosis cell surface markers and finally produce autoantibody and Natalizumab, a humanized MAb was approved by FDA in present auto antigen to T cells at increased rates.
[ [74] mandatory patient registration and periodic follow-up. [63] iodiotype vaccine has been developed from proteins derived from the outer membrane proteins of Neisseria meningitidis B. 1E10 vaccine, is an anti-idiotype vaccine designed to mimic Omalizumab MAb has shown promise in allergic asthma the N-Glycolyl-GM3 gangliosides. This monoclonal antibody is [ Table 1 ]. It acts by binding to IgE thus preventing IgE from an Ab2-type-antibody which recognizes the Ab1 antibody called binding to mast cells. Omalizumab has shown to reduce serum P3, the latter is a MAb that specifically recognize gangliosides IgE levels, reduce inhaled steroid consumption and was also as antigens. Results of the phase I clinical trials proved that well tolerated by children and adults. [64] the three vaccines were safe and able to elicit specific antibody responses. Phase II trials are being undertaken in several Data suggest that MAbs directed against T-cell mediated neoplastic diseases, with these vaccines. [74] inflammation are clinically effective in the treatment of psoriasis. immunologically responding metastatic colorectal carcinoma MAbs directed against key components of inflammatory process patients with SCV 106 leads to slowing of disease progression,
Anti-

Asthma Psoriasis
Vaccination of have been studied for safer, selective, and effective immunosuppressant agent as psoriasis is a T-cell mediated autoimmune disease in which proinflammatory Th-1 cytokine play an essential role. Efalizumab is the agent that is near the market launch [ Table 1 ]. It is a humanized MAb that interrupts the interaction between the T-cell surface molecule lymphocyte function associated antigen LFA1 (composed of 2 subunits CD11a and CD18) and intercellular adhesion molecule1, which is found on the surface of antigen-presenting cells. It is used as a once weekly self-administered subcutaneous injection. [65, 66] It is administered every other week and carries a risk of tuberculosis reactivation, serious infections, and demyelinating disease.
Juvenile diabetes
Anti-CD3 MAb is in phase II trial for type I juvenile DM. This MAb targets an antigen expressed on T lymphocytes that is responsible for destruction of islet cells of pancreas tumor dissemination and significantly prolongs survival time. [75] Increased CMI responses to HIV-1 envelope glycoprotein measured by lymphocyte proliferation were associated with HIV-1 recombinant envelope glycoprotein vaccines.
[76] HIV-1 specific T helper cell responses can be successfully increased by therapeutic immunization in individuals with chronic infection on suppressive antiretroviral therapy. [77] Further studies will be needed to determine whether the augmentation of these responses correlate with long-term clinical benefits.
In diagnostics
Generally, MAbs are being used as invaluable reagents in diagnostics. In fact, they have played a major role in deciphering the functions of various bio-molecules in cryptic biosynthetic pathways. These have also become the reagents of choice for identification and characterization of tumor specific antigens and have become a valuable tool in the classification of cancer. [78] The ability of MAb to accumulate at tumor sites, led to its approval for localization of cancer, for example, igorvomab for ovarian cancer, teenamab K-1 for melanoma, votumab, and acrolunumab for colorectal cancer and sulemab for detection of infection. [19] MAbs will be useful agents for diagnostic imaging of prostate cancer. [79] MAbs are used commercially in pregnancy tests where they are directed against proteins in urine, determine glucose level in diabetes, detect antibiotic residues in milk, and to detect salmonella too. ) .
Conclusion
